Table 1.

Patient response to combined Campath-1H and fludarabine

UPNBinet stage (before)Marrow biopsy appearances% clonal B cells in marrowB lymphocytes × 109/LMaximal lymphadenopathyComplete blood countNCI response
BeforeAfterBeforeAfterBeforeAfterBeforeAfterBeforeAfter
1 C Heavy nodular Normal 2.5 < 0.05 MRD− 0.16 0.54 2-cm spleen Spleen tip Hb 13.7 g/dL Hb 12.8 g/dL PR  
1.5-cm nodes ANC 1.6 × 109/L ANC 3.2 × 109/L  
Plt 61 × 109/L Plt 69 × 109/L  
2 B Heavy diffuse Heavy diffuse 71.6 13.5 17.3 0.01 Bulky intra-abdominal nodes No change Hb 8.3 g/dL Hb 7.4 g/dL PD  
ANC 2.1 × 109/L ANC 1.5 × 109/L  
Plt 60 × 109/L Plt 92 × 109/L  
3 B Heavy diffuse Normal 31 3 MRD+ 0.01 0.03 Extensive bulky disease Resolution Hb 14.6 g/dL Hb 15.6 g/dL CR  
ANC 4.6 × 109/L ANC 2.6 × 109/L  
Plt 159 × 109/L Plt 153 × 109/L 
4 C Heavy nodular Hypocellular 78.7 0.8 MRD+ 0.3 0.01 2-cm nodes widespread None palpable 50% decrease on CT Hb 11.0 g/dL Hb 10.6 g/dL PR 
No CLL ANC 1.2 × 109/L ANC 0.51 × 109/L  
 Plt 135 × 109/L Plt 21 × 109/L  
5 C Heavy nodular Normal 75 < 0.05 MRD− 1.1 0.33 3-cm nodes Spleen tip only Hb 11.9 g/dL Hb 13.2 g/dL PR  
6-cm spleen ANC 1.8 × 109/L ANC 1.5 × 109/L  
Plt 58 × 109/L Plt 117 × 109/L 
6 B Moderate nodular Hypocellular 53.2 0.35 MRD+ 12.0 1.65 1-cm nodes < 1 cm cervical nodes Hb 14.9 g/dL Hb 11.9 g/dL PR  
No CLL ANC 3.3 × 109/L ANC 1.7 × 109/L  
 Plt 226 × 109/L Plt 126 × 109/L 
UPNBinet stage (before)Marrow biopsy appearances% clonal B cells in marrowB lymphocytes × 109/LMaximal lymphadenopathyComplete blood countNCI response
BeforeAfterBeforeAfterBeforeAfterBeforeAfterBeforeAfter
1 C Heavy nodular Normal 2.5 < 0.05 MRD− 0.16 0.54 2-cm spleen Spleen tip Hb 13.7 g/dL Hb 12.8 g/dL PR  
1.5-cm nodes ANC 1.6 × 109/L ANC 3.2 × 109/L  
Plt 61 × 109/L Plt 69 × 109/L  
2 B Heavy diffuse Heavy diffuse 71.6 13.5 17.3 0.01 Bulky intra-abdominal nodes No change Hb 8.3 g/dL Hb 7.4 g/dL PD  
ANC 2.1 × 109/L ANC 1.5 × 109/L  
Plt 60 × 109/L Plt 92 × 109/L  
3 B Heavy diffuse Normal 31 3 MRD+ 0.01 0.03 Extensive bulky disease Resolution Hb 14.6 g/dL Hb 15.6 g/dL CR  
ANC 4.6 × 109/L ANC 2.6 × 109/L  
Plt 159 × 109/L Plt 153 × 109/L 
4 C Heavy nodular Hypocellular 78.7 0.8 MRD+ 0.3 0.01 2-cm nodes widespread None palpable 50% decrease on CT Hb 11.0 g/dL Hb 10.6 g/dL PR 
No CLL ANC 1.2 × 109/L ANC 0.51 × 109/L  
 Plt 135 × 109/L Plt 21 × 109/L  
5 C Heavy nodular Normal 75 < 0.05 MRD− 1.1 0.33 3-cm nodes Spleen tip only Hb 11.9 g/dL Hb 13.2 g/dL PR  
6-cm spleen ANC 1.8 × 109/L ANC 1.5 × 109/L  
Plt 58 × 109/L Plt 117 × 109/L 
6 B Moderate nodular Hypocellular 53.2 0.35 MRD+ 12.0 1.65 1-cm nodes < 1 cm cervical nodes Hb 14.9 g/dL Hb 11.9 g/dL PR  
No CLL ANC 3.3 × 109/L ANC 1.7 × 109/L  
 Plt 226 × 109/L Plt 126 × 109/L 

All posttreatment assessments are at 2 months after therapy except UPN2 in whom assessments are given for the end of therapy.

NCI indicates National Cancer Institute; Hb, hemoglobin; ANC, absolute neutrophil count; Plt, platelet; PR, partial response; CR, complete response; and PD, progressive disease.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal